Get the Stockscreener App
0.9301
1.61%
-0.0152
After Hours:
.9301
Accelerate Diagnostics Inc stock is currently priced at $0.9301, with a 24-hour trading volume of 4,924.
It has seen a -1.61% decreased in the last 24 hours and a -3.14% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.9278 pivot point. If it approaches the $0.9675 resistance level, significant changes may occur.
Previous Close:
$0.9453
Open:
$0.92
24h Volume:
4,924
Market Cap:
$20.15M
Revenue:
$12.00M
Net Income/Loss:
$-63.23M
P/E Ratio:
-0.1182
EPS:
-7.87
Net Cash Flow:
$-43.02M
1W Performance:
+8.28%
1M Performance:
-3.14%
6M Performance:
-84.70%
1Y Performance:
+3.34%
1D Range:
$0.8854
$0.945
52W Range:
$0.651
$8.72
Accelerate Diagnostics Inc Stock (AXDX) Company Profile
Name
Accelerate Diagnostics Inc
Sector
Industry
Phone
520 365 3100
Address
3950 South Country Club Road, Suite 470 4th Floor, Tucson, AZ
Accelerate Diagnostics Inc Stock (AXDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-22 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-08-20 | Initiated | BTIG Research | Neutral |
| Aug-07-20 | Upgrade | Craig Hallum | Hold → Buy |
| Sep-27-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-18 | Initiated | Craig Hallum | Hold |
| Dec-13-17 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-12-17 | Resumed | BTIG Research | Buy |
| Mar-24-16 | Initiated | JP Morgan | Overweight |
| Dec-16-15 | Initiated | Piper Jaffray | Overweight |
View All
Accelerate Diagnostics Inc Stock (AXDX) Latest News
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
US Stocks Higher; Schlumberger Earnings Beat Estimates
Benzinga
Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics
Zacks Investment Research
Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System
Zacks Investment Research
Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research
Accelerate Diagnostics Inc Stock (AXDX) Financials Data
Accelerate Diagnostics Inc (AXDX) Revenue 2024
AXDX reported a revenue (TTM) of $12.00 million for the quarter ending September 30, 2023, a -8.52% decline year-over-year.
Accelerate Diagnostics Inc (AXDX) Net Income 2024
AXDX net income (TTM) was -$63.23 million for the quarter ending September 30, 2023, a +10.55% increase year-over-year.
Accelerate Diagnostics Inc (AXDX) Cash Flow 2024
AXDX recorded a free cash flow (TTM) of -$43.02 million for the quarter ending September 30, 2023, a +17.22% increase year-over-year.
Accelerate Diagnostics Inc (AXDX) Earnings per Share 2024
AXDX earnings per share (TTM) was -$6.00 for the quarter ending September 30, 2023, a +38.52% growth year-over-year.
About Accelerate Diagnostics Inc
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
1.69%
0.48%
Cap:
|
Volume (24h):